The growing use of effective treatment strategies for metastatic cancer in the brain has not been documented in certain patient populations.
A recent study identified substantial barriers to standard-of-care therapy for limited-stage small cell lung cancer, including government insurance coverage.
Receipt of treatment for multiple myeloma varies greatly among racial or ethnic minorities.
Second malignant neoplasms have increased among younger patients with multiple myeloma.
Elderly patients with acute myeloid leukemia faced high health care costs in their first year following diagnosis.
Patients with acute leukemia exhibited a high rate of venous thromboembolism, along with high recurrence rates.
Palliative care utilization among patients with hematologic malignancies remains extremely low.
Elderly patients with untreated early-stage triple-negative breast cancer exhibited a higher mortality rate than patients treated with neoadjuvant or adjuvant therapy.
Results of a recent study showed that the prognostic implications of patient-specific and tumor biological features vary significantly across age-groups of patients with multiple myeloma.
A 5-year sensitivity analysis of a recent trial showed improved efficacy outcomes and toxicity profiles for patients receiving a new adjuvant therapy for HER2-positive breast cancer.